[ad_1]
LONDON: Moderna will be able to produce 500 million doses of its COVID-19 vaccine in 2021, Chief Executive Officer Stéphane Bancel said on Friday (December 4).
The company has filed applications for an emergency use authorization in the United States and the European Union after full results from a late-stage study showed the vaccine was 94.1 percent effective with no problems of serious security.
“For 500 million, I am very confident that we will get there (2021),” Bancel told the Nasdaq Investor Conference.
He also said the company could maintain a $ 37 price premium for its vaccine doses, although the price premium is expected to drop to $ 25 for high-volume supplies, such as from the US government.
The Food and Drug Administration is scheduled to hold an advisory committee meeting on December 17 to discuss the company’s request for emergency clearance for its COVID-19 vaccine.
Bancel said the company has seen renewed demand from many countries seeking additional doses after it reported clinical data.
Earlier on Friday, Moderna extended its contract with the Israeli Ministry of Health to supply an additional 4 million doses of its COVID-19 vaccine candidate.
The company said Thursday it would supply up to 125 million doses of the vaccine by the first quarter of 2021.
CHECK THIS: Our comprehensive coverage of the coronavirus outbreak and its developments
Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak: https://cna.asia/telegram
